Search Results - "Waal, Esther de"

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study by Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, Zweegman, Sonja

“…Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a…”
Get full text

Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands by Waal, Esther G. M., Leene, Marnix, Veeger, Nic, Vos, Hanneke J., Ong, Francisca, Smit, Wilma G. J. M., Hovenga, Sjoerd, Hoogendoorn, Mels, Hogenes, Marieke, Beijert, Max, Diepstra, Arjan, Vellenga, Edo

“…Plasmacytoma is characterized by a local accumulation of monoclonal plasma cells without criteria for multiple myeloma (MM). The current treatment regimen is…”
Get full text

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting by de Waal, Esther G. M., Glaudemans, Andor W. J. M., Schröder, Carolien P., Vellenga, Edo, Slart, Riemer H. J. A.

“…Multiple myeloma (MM) is characterized by a monoclonal plasma cell population in the bone marrow. Lytic lesions occur in up to 90 % of patients. For many…”
Get full text

Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients by Waal, Esther G. M., Munck, Linda, Hoogendoorn, Mels, Woolthuis, Gerhard, Velden, Annette, Tromp, Yvonne, Vellenga, Edo, Hovenga, Sjoerd

“…Summary Combination therapy for longer periods but at low dose might be an effective and tolerable manner to treat patients with relapsed multiple myeloma…”
Get full text

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study by Brink, Mirian, Groen, Kaz, Sonneveld, Pieter, Minnema, Monique C., Broijl, Annemiek, Dinmohamed, Avinash G., van der Spek, Ellen, Levin, Mark-David, Ypma, Paula F., de Waal, Esther, Posthuma, Eduardus F. M. Ward, Zweegman, Sonja, van de Donk, Niels W. C. J.

“…Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at…”
Get full text

Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema by Bos, Reinhard, de Waal, Esther G. M., Kuiper, Hilde, Hazenberg, Bouke P. C., Vellenga, Edo

Get full text

Is FDG PET a Better Imaging Tool Than Somatostatin Receptor Scintigraphy in Patients With Relapsing Multiple Myeloma? by de Waal, Esther G.M, Slart, Riemer H.J.A, Vellenga, Edo

“…PURPOSEOsseous involvement defined by lytic bone lesions is shown by skeletal survey in multiple myeloma (MM). This technique has limitations because it…”
Get full text

18F-FDG PET Increases Visibility of Bone Lesions in Relapsed Multiple Myeloma: Is This Hypoxia-Driven? by de Waal, Esther G.M, Slart, Riemer H.J.A, Leene, Marnix J, Kluin, Philip M, Vellenga, Edo

“…INTRODUCTIONWhole-body x-ray (WBX) is used for detecting skeleton abnormalities in patients with multiple myeloma (MM). An alternative might be F-FDG PET,…”
Get full text

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial by Minnema, Monique C, Nasserinejad, Kazem, Hazenberg, Bouke, Hegenbart, Ute, Vlummens, Philip, Ypma, Paula F, Kröger, Nicolaus, Wu, Ka Lung, Kersten, Marie Jose, Schaafsma, M Ron, Croockewit, Sandra, de Waal, Esther, Zweegman, Sonja, Tick, Lidwien, Broijl, Annemieke, Koene, Harry, Bos, Gerard, Sonneveld, Pieter, Schönland, Stefan

“…This prospective, multicenter, phase II study investigated the use of four cycles of bortezomib-dexamethasone induction treatment, followed by high-dose…”
Get full text

Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report by van Bentum, Renée, Nieken, Judith, de Waal, Esther, Hoogendoorn, Mels

“…Patients with multiple myeloma (MM) are known to be immune incompetent and experience higher incidences of infectious diseases. However, infective endocarditis…”
Get full text

P899: HOVON 104; LONG TERM FOLLOW‐UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS by Minnema, Monique, Nasserinejad, Kazem, Hegenbart, Ute, Ypma, Paula, Lung Wu, Ka, José Kersten, Marie, Croockewit, Sandra, Waal, Esther, Zweegman, Sonja, Tick, Lidwien, Broijl, Annemiek, Schönland, Stefan

Get full text

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Get full text

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes by Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., Heer, Koen, Leys, Rineke B. L., Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., Spek, Ellen, Klein, Saskia K., Donk, Niels W. C. J., Ypma, Paula F., Zweegman, Sonja

Get full text

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry by Wester, Ruth, Dinmohamed, Avinash G., Holt, Bronno, Zweegman, Sonja, Minnema, Monique, Croockewit, Sandra, Levin, Mark‐David, Libourel, Eduard, Waal, Esther, Sonneveld, Pieter, Cornelissen, Jan, Blijlevens, Nicole, Broijl, Annemiek

“…Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated…”
Get full text

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial by van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C, Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A, Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K, Delforge, Michel, Levin, Mark-David, Bos, Gerard M, Jie, Kon-Siong G, Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G, Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M

“…In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and…”
Get full text

P877: IXAZOMIB DARATUMUMAB AND LOW‐DOSE DEXAMETHASONE IN INTERMEDIATE‐FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY by Groen, Kaz, Stege, Claudia, Nasserinejad, Kazem, Heer, Koen, Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka‐Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie‐Christiane, Donk, Niels W.C.J., Timmers, Gert‐Jan, Boer, Fransien, Tick, Lidwine W., Spek, Ellen, Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., Levin, Mark‐David, Ypma, Paula F., Zweegman, Sonja

Get full text

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study by Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia, Van Kampen, Roel JW, Van Der Spek, Ellen, Bilgin, Yavuz M, Thielen, Noortje, Nijhof, Inger S., Ludwig, Inge, De Waal, Esther G.M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert Jan, Regelink, Josien C, Westerman, Matthijs, de Heer, Koen, Vekemans, Marie Christiane, Durdu-Rayman, Nazik, Graauw, Nicole de, Seefat, Maarten R., van de Donk, Niels WCJ, Ypma, Paula F, Nasserinejad, Kazem, Zweegman, Sonja

“…Introduction The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on…”
Get full text

P-353 Stem-Cell Mobilization and Transplantation in Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib-Lenalidomide-Dexamethasone With or Without Isatuximab: Results From the IsKia Trial by Mina, Roberto, Gay, Francesca, Roeloffzen, Wilfried, Dimopoulos, Meletios, Rosiñol, Laura, van der Klift, Marjolein, Oriol, Albert, Katodritou, Eirini, Wu, Ka Lung, Rodríguez-Otero, Paula, Hájek, Roman, Mangiacavalli, Silvia, van Duin, Mark, D'Agostino, Mattia, de Waal, Esther, Ocio, Enrique, Levin, Mark-David, Manteca, María-Victoria Mateos, Slørdahl, Tobias, Schjesvold, Fredrik, Bladé, Joan, Einsele, Hermann, Sonneveld, Pieter, Boccadoro, Mario, Broijl, Annemiek

Get full text

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, Van Kampen, Roel J.W., Leijs, Maria B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila, Velders, Gerjo A., Vekemans, Marie-Christiane, van de Donk, Niels W.C.J., Timmers, Gert-Jan, Sonneveld, Pieter, Seefat, Maarten R., Croon-de Boer, Fransien, Tick, Lidwine W., van der Spek, Ellen, De Waal, Esther G.M., Sohne, Maaike, Ypma, Paula F, Nijhof, Inger S., Klein, Saskia K., Levin, Mark-David, Zweegman, Sonja

“…Introduction Non-transplant eligible newly diagnosed multiple myeloma (NTE-NDMM) patients have a heterogeneous clinical outcome, which can be partly explained…”
Get full text

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study by Stege, Claudia A.M., Nasserinejad, Kazem, Levin, Mark-David, Thielen, Noortje, Klein, Saskia K., Ludwig, Inge, Westerman, Matthijs, Ypma, Paula F, Bilgin, Yavuz, Sohne, Maaike, Waal, Esther de, van de Donk, Niels WCJ, Sonneveld, Pieter, Zweegman, Sonja

“…Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagnosed multiple myeloma (nte-NDMM) patients also benefit from…”
Get full text